Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Liabilities and Shareholders Equity (2020 - 2025)

Historic Liabilities and Shareholders Equity for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to $262.2 million.

  • TScan Therapeutics' Liabilities and Shareholders Equity fell 2465.38% to $262.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 232.5%. This contributed to the annual value of $371.1 million for FY2024, which is 3636.57% up from last year.
  • TScan Therapeutics' Liabilities and Shareholders Equity amounted to $262.2 million in Q3 2025, which was down 2465.38% from $298.6 million recorded in Q2 2025.
  • TScan Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $374.9 million during Q2 2024, with a 5-year trough of $130.0 million in Q2 2021.
  • Over the past 5 years, TScan Therapeutics' median Liabilities and Shareholders Equity value was $251.5 million (recorded in 2024), while the average stood at $249.5 million.
  • In the last 5 years, TScan Therapeutics' Liabilities and Shareholders Equity soared by 27819.57% in 2021 and then plummeted by 2465.38% in 2025.
  • TScan Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $188.1 million in 2021, then grew by 5.84% to $199.1 million in 2022, then soared by 36.7% to $272.1 million in 2023, then surged by 36.37% to $371.1 million in 2024, then dropped by 29.34% to $262.2 million in 2025.
  • Its Liabilities and Shareholders Equity was $262.2 million in Q3 2025, compared to $298.6 million in Q2 2025 and $332.7 million in Q1 2025.